崔炜

• 1:河北医科大学第二医院河北省心脑血管病研究所心内一科

摘要(Abstract)：

<正>经皮冠状动脉介入治疗(PCI)已成为冠心病的标准治疗方法之一。其中,支架置入术是冠心病介入治疗的最基本手段。支架置入术后通常要考虑支架内再狭窄和支架内血栓形成两方面的问题。为防止支架内再狭窄,近年临床上普遍采用药物洗脱支架(drug-eluting stent,DES)。然而,药物洗脱支架虽然能降低支架置入术后再狭窄的发生率,但由于药物及涂层本身同时抑制了支架表面的内皮化,从而增加了

关键词(KeyWords)： 抗血小板治疗;药物洗脱支架

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 崔炜

参考文献(References)：

• [1]Garg S,Serruys PW.Coronary stents:current status.J Am Coll Cardiol,2010,56:S1-S42.
• [2]Gurbel PA,Mahla E,Tantry US.The enigmatic search for optimal DAPT duration.Eur Heart J,2014,35:951-954.
• [3]中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012(简本).中华心血管病杂志,2012,40:271-277.
• [4]Montalescot G,Sechtem U,Achenbach S,et al.2013 ESC guidelines on the management of stable coronary artery disease:The Task Force on the management of stable coronary artery disease of the European Society of Cardiology.Eur Heart J,2013,34:2949-3003.
• [5]O'Gara PT,Kushner FG,Ascheim DD,et al.2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction:Executive Summary:A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines:Developed in Collaboration With the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions.Catheter Cardiovasc Interv,2013,82:E1-E27.
• [6]Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for CardioThoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur Heart J,2014,35:2541-2619.
• [7]Kristensen SD,Knuuti J,Saraste A,et al.2014 ESC/ESA Guidelines on non-cardiac surgery:cardiovascular assessment and management:The Joint Task Force on non-cardiac surgery:cardiovascular assessment and management of the European Society of Cardiology(ESC)and the European Society of Anaesthesiology(ESA).Eur Heart J,2014,35:2383-2431.
• [8]D'Ascenzo F,Bollati M,Clementi F,et al.Incidence and predictors of coronary stent thrombosis:evidence from an international collaborative meta-analysis including 30 studies,221,066 patients,and 4276 thromboses.Int J Cardiol,2013,167:575-584.
• [9]Zimarino M,Corazzini A,Ricci F,et al.Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations:a meta-analysis of randomized and observational Studies.JACC Cardiovasc Interv,2013,6:687-695.
• [10]Palmerini T,Biondi-Zoccai G,Della RD,et al.Stent thrombosis with drug-eluting and bare-metal stents:evidence from a comprehensive network meta-analysis.Lancet,2012,379:1393-1402.
• [11]Philip F,Agarwal S,Bunte MC,et al.Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents:network meta-analysis of primary percutaneous coronary intervention trials in ST-segment-elevation myocardial infarction.Circ Cardiovasc Interv,2014,7:49-61.
• [12]Baber U,Mehran R,Sharma SK,et al.Impact of the everolimuseluting stent on stent thrombosis:a meta-analysis of 13randomized trials.J Am Coll Cardiol,2011,58:1569-1577.
• [13]Palmerini T,Kirtane AJ,Serruys PW,et al.Stent thrombosis with everolimus-eluting stents:meta-analysis of comparative randomized controlled trials.Circ Cardiovasc Interv,2012,5:357-364.
• [14]Li P,Liu JP.Long-term risk of late and very late stent thrombosis in patients treated with everolimus against paclitaxel-eluting stents:an updated meta-analysis.Coron Artery Dis,2014,25:369-377.
• [15]Niu X,Yang C,Chen D,et al.Impact of drug-eluting stents with different coating strategies on stent thrombosis:A metaanalysis of 19 randomized trials.Cardiol J,2014,21:557-568.
• [16]Zhang J.Stent thrombosis in patients with coronary artery disease treated with biodegradable polymer drug-eluting stents:an update meta-analysis.Int Heart J,2014,55:213-218.
• [17]Cockburn J,Pareek N,Poliacikova P,et al.Clinical outcomes with 6 months dual antiplatelet therapy after implantation of biolimus-A9 drug eluting coronary stents.Int J Cardiol,2014,172:185-189.
• [18]Han Y,Jing Q,Xu B,et al.Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in"real-world"practice:18-month clinical and 9-month angiographic outcomes.JACC Cardiovasc Interv,2009,2:303-309.
• [19]Zhang L,Li Y,Jing QM,et al.Dual antiplatelet therapy over 6months increases the risk of bleeding after biodegradable polymercoated sirolimus eluting stents implantation:insights from the CREATE study.J Interv Cardiol,2014,27:119-126.
• [20]Urban P,Abizaid A,Banning A,et al.Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population:a report from the e-SELECT(Multi-Center Post-Market Surveillance)registry.J Am Coll Cardiol,2011,57:1445-1454.
• [21]Hawn MT,Graham LA,Richman JS,et al.Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents.JAMA,2013,310:1462-1472.
• [22]Sudhir K,Hermiller JB,Ferguson JM,et al.Risk factors for coronary drug-eluting stent thrombosis:influence of procedural,patient,lesion,and stent related factors and dual antiplatelet therapy.ISRN Cardiol,2013,2013:748736.
• [23]Silber S,Kirtane AJ,Belardi JA,et al.Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.Eur Heart J,2014,35:1949-1956.
• [24]Gilard M,Barragan P,AAL N,et al.6-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients nonresistant to aspirin:The randomized multicenter ITALIC trial.J Am Coll Cardiol,2015,65:777-786.
• [25]Colombo A,Chieffo A,Frasheri A,et al.Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy:The SECURITY randomized clinical trial.J Am Coll Cardiol,2014,64:2086-2097.
• [26]Elmariah S,Mauri L,Doros G,et al.Extended duration dual antiplatelet therapy and mortality:a systematic review and metaanalysis.Lancet,2015,385:792-798.
• [27]Christodoulidis G,Baber U,Mehran R.Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome.Curr Opin Cardiol,2014,29:301-306.
• [28]Pandit A,Giri S,Hakim FA,et al.Shorter(/=12 months)duration dual antiplatelet therapy after drug eluting stents:A meta-analysis of randomized clinical trials.Catheter Cardiovasc Interv,2015,85:34-40.
• [29]El-Hayek G,Messerli F,Bangalore S,et al.Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents.Am J Cardiol,2014,114:236-242.
• [30]Zhang T,Shen L,Hu L,et al.Optimal duration of dualantiplatelet therapy following drug-eluting stent implantation:a meta-analysis.J Clin Pharmacol,2013,53:345-351.
• [31]Jeger RV,Pfisterer ME,Sorensen R,et al.Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes:Importance of case fatality rates and effective treatment durations.Am Heart J,2014,168:698-705.
• [32]Collet JP,Silvain J,Barthelemy O,et al.Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation(ARCTIC-Interruption):a randomised trial.Lancet,2014,384:1577-1585.
• [33]Park SJ,Park DW,Kim YH,et al.Duration of dual antiplatelet therapy after implantation of drug-eluting stents.N Engl J Med,2010,362:1374-1382.
• [34]Valgimigli M,Borghesi M,Tebaldi M,et al.Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent?A pre-specified analysis from the Prolonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia stud Y(PRODIGY).Eur Heart J,2013,34:909-919.
• [35]Tomey M,Mehran R.Dual antiplatelet therapy dilemmas:duration and choice of antiplatelets in acute coronary syndromes.Curr Cardiol Rep,2013,15:405.
• [36]Park SJ,Kang SM,Park DW.Dual antiplatelet therapy after drug-eluting stents:defining the proper duration.Coron Artery Dis,2014,25:83-89.
• [37]Valgimigli M,Campo G,Monti M,et al.Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting:a randomized multicenter trial.Circulation,2012,125:2015-2026.
• [38]Kim BK,Hong MK,Shin DH,et al.A new strategy for discontinuation of dual antiplatelet therapy:the RESET Trial(REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).J Am Coll Cardiol,2012,60:1340-1348.
• [39]Gwon HC,Hahn JY,Park KW,et al.Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents:the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting(EXCELLENT)randomized,multicenter study.Circulation,2012,125:505-513.
• [40]Feres F,Costa RA,Abizaid A,et al.Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents:the OPTIMIZE randomized trial.JAMA,2013,310:2510-2522.
• [41]Yu X,Chen F,He J,et al.Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.Coron Artery Dis,2013,24:217-223.
• [42]Varenhorst C,Jensevik K,Jernberg T,et al.Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.Eur Heart J,2014,35:969-978.
• [43]D'Ascenzo F,Colombo F,Barbero U,et al.Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with percutaneous coronary intervention:systematic review and meta-analysis.J Interv Cardiol,2014,27:233-241.
• [44]Ho PM,Peterson ED,Wang L,et al.Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.JAMA,2008,299:532-539.
• [45]Charlot M,Nielsen LH,Lindhardsen J,et al.Clopidogrel discontinuation after myocardial infarction and risk of thrombosis:a nationwide cohort study.Eur Heart J,2012,33:2527-2534.
• [46]Boggon R,van Staa TP,Timmis A,et al.Clopidogrel discontinuation after acute coronary syndromes:frequency,predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort(MINAP-GPRD).Eur Heart J,2011,32:2376-2386.
• [47]Stephenson JJ,Chang CL,Devecchis WG,et al.Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the US.Curr Med Res Opin,2011,27:1079-1087.